Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Karyopharm Therapeutics (KPTI) over the last 6 years, with Q4 2025 value amounting to $1.5 million.

  • Karyopharm Therapeutics' Cost of Revenue rose 1149.51% to $1.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.9 million, marking a year-over-year decrease of 96.55%. This contributed to the annual value of $5.9 million for FY2025, which is 96.55% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Cost of Revenue of $1.5 million as of Q4 2025, which was up 1149.51% from $2.1 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Cost of Revenue peaked at $2.1 million during Q3 2025, and registered a low of $589000.0 during Q3 2021.
  • In the last 5 years, Karyopharm Therapeutics' Cost of Revenue had a median value of $1.3 million in 2025 and averaged $1.3 million.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Cost of Revenue surged by 15175.2% in 2022, and later crashed by 3192.05% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Cost of Revenue stood at $742000.0 in 2021, then soared by 151.75% to $1.9 million in 2022, then fell by 20.45% to $1.5 million in 2023, then dropped by 10.43% to $1.3 million in 2024, then grew by 11.5% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q4 2025, $2.1 million for Q3 2025, and $1.1 million during Q2 2025.